Integral Derivatives’s Alexion Pharmaceuticals ALXN Stock Holding History

Integral Derivatives’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$1.91M	Buy	17,100 +9,400	+122%	+$1.12M	0.05%	122
2017 Q4	$921K	Sell	7,700 -10,400	-57%	-$1.27M	0.02%	508
2017 Q3	$2.54M	Sell	18,100 -3,900	-18%	-$530K	0.05%	257
2017 Q2	$2.68M	Buy	22,000 +16,800	+323%	+$1.96M	0.06%	240
2017 Q1	$630K	Sell	5,200 -20,500	-80%	-$2.64M	0.01%	670
2016 Q4	$3.14M	Buy	+25,700	New	+$3.14M	0.06%	213
2016 Q3	–	Sell	-5,800	Closed	-$677K	–	1199
2016 Q2	$677K	Buy	+5,800	New	+$823K	0.02%	522
2016 Q1	–	Sell	-2,700	Closed	-$515K	–	1171
2015 Q4	$515K	Hold	2,700	–	–	0.01%	646
2015 Q3	$422K	Hold	2,700	–	–	0.01%	753
2015 Q2	$488K	Hold	2,700	–	–	0.01%	726
2015 Q1	$468K	Sell	2,700 -2,000	-43%	-$362K	0.01%	718
2014 Q4	$870K	Buy	4,700 +2,000	+74%	+$371K	0.02%	720
2014 Q3	$448K	Hold	2,700	–	–	0.01%	1007
2014 Q2	$422K	Buy	+2,700	New	+$426K	0.01%	982

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Integral Derivatives's ALXN Position: Q1 2018 in Review

Integral Derivatives sold out of Alexion Pharmaceuticals (ALXN) in Q1 2018, closing a stake of 15,780 shares — an estimated $1.89M sold.

Integral Derivatives first reported a position in ALXN in Q4 2013 and held it in 6 quarters. The position peaked at $2.91M in Q3 2017. 596 funds tracked by Wall St. Rank hold ALXN as of Q1 2018.

Integral Derivatives reported no remaining Alexion Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Integral Derivatives sold 15,780 Alexion Pharmaceuticals shares in Q1 2018, an estimated $1.89M.
Integral Derivatives first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 6 quarters.
Integral Derivatives's Alexion Pharmaceuticals position peaked at $2.91M in Q3 2017.
596 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.